ZHBIO(300653)2025-05-15 10:52Group 1: Financial Performance - The company's sales revenue in Q1 2025 showed positive growth driven by both existing and new products [4] - In Q1 2025, net profit continued to decline significantly, with sales expenses increasing compared to the same period last year [4] - The overall sales volume has been growing over the years, with a 9.21% growth expected in 2024 despite a severe slowdown in 2023 [5] Group 2: Market Challenges - The decline in revenue and profit in 2024 was influenced by multiple factors, including price optimization of oral products and market demand fluctuations [5] - The company faced challenges with the active biological bone product due to limited sales scale and market conditions [5] - The first quarter of 2025 recorded the lowest gross and net profit since the company went public, indicating a potential ongoing trend [5] Group 3: Product Development and Strategy - The company is focusing on enhancing market promotion for active biological bone products and implementing precise marketing strategies in the oral field [4] - There are plans to expand the indications for active biological bone and to conduct comparative experiments with autologous bone [6] - The company is actively working on the registration and market introduction of new products, including calcium-silicon biological ceramics [10] Group 4: Investor Relations and Future Outlook - The company is committed to improving sales volume and achieving sustainable development despite current challenges [5] - There is an ongoing effort to enhance brand recognition and market coverage for active biological bone products [8] - The company is planning to disclose its profit distribution plan and net profit targets for 2025 in future announcements [30]